To date, the extent of glutamine dependency in cancer cells has been found to be modulated by oncogenic or tumor suppressor gene alterations, which are summarized in Fig. 2A. MYC is the third most commonly oncogene in human cancer [82]. This evidence concerns the gene MYC and cancer.